Cancer-associated prothrombotic pathways: leucocytosis, but not thrombocytosis, correlates with venous thromboembolism in women with ovarian cancer.
Javier López-SalazarLaura A Ramírez-TiradoNora Gómez-ContrerasIrlanda Pacheco-BravoEvelyn CortésDolores GallardoArrieta OscarGabriela Cesarman-MausPublished in: Internal medicine journal (2021)
Risk factors for venous thromboembolism in cancer vary between tumours. Leucocytosis, thrombocytosis, tumour histology and vascular compression may drive thrombosis in ovarian cancer. Thrombosis developed in 13.4% of our patients. Higher median leucocyte, neutrophil and monocyte counts were related to thrombosis. Thrombocytosis >350 × 109 /L was frequent (63.8%), but not predictive of thrombosis. Identification of prothrombotic biomarkers may help personalise preventive treatments.
Keyphrases
- venous thromboembolism
- pulmonary embolism
- end stage renal disease
- direct oral anticoagulants
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- papillary thyroid
- peritoneal dialysis
- squamous cell carcinoma
- endothelial cells
- atrial fibrillation
- squamous cell
- lymph node metastasis
- bioinformatics analysis
- drug induced